This episode is part of ACC’s ongoing initiative on Implementing the 2026 Dyslipidemia Guidelines. Explore key updates from the 2026 Guideline for the Treatment of Dyslipidemia with Drs. Eugenia Gianos and Michael Blaha, including connections to the 2026 Cardiovascular-Kidney-Metabolic Syndrome Guideline. Learn practical strategies for implementing lipid management recommendations and building collaborative Lipid and Cardiometabolic Clinic models into clinical practice.

This podcast is part of the ACC’s Implementing the 2026 Dyslipidemia Guidelines: From Risk Stratification to Personalized Treatment initiative, supported by Merck & Co, and Eli Lilly and Company.

Related References:

1. Blumenthal, R, Morris, P, Gaudino, M. et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. JACC. 2026 May, 87 (19) 2624–2757. https://doi.org/10.1016/j.jacc.2025.11.016